Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7782 in advanced malignant cancer
NCT07123129Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-7782 in advanced cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose Limited Toxicity at 21 days, Maximum Tolerated Dose at 6 months and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
SHR-7782
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT07123129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123129.